Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 67 Stomach Neoplasms 4 Ovarian Neoplasms 4 Neoplasms 4 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 4 Inflammatory Breast Neoplasms 3 Breast Neoplasms, Male 3 Solid Tumor 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 HER2-positive Breast Cancer 2 Colonic Neoplasms 2 Carcinoma, Ductal, Breast 2 Urinary Bladder Neoplasms 1 Solid Cancers 1 Patient Preference 1 Neoplasms, Unknown Primary 1 Metastatic HER2-Positive Breast Cancer 1 Lung Neoplasms 1 Her2-Positive Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-Positive Early Breast Cancer 1 HER2 Positive Breast Cancer 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Elderly Metastatic Breast Cancer Population 1 Colorectal Neoplasms 1 Carcinoma, Neuroendocrine 1 Biliary Tract Neoplasms 1

Interventions

Trastuzumab 3 pyrotinib 1 pertuzumab 1 copanlisib 1 Vinorelbine 1 Lapatinib 1 Docetaxel 1 Carboplatin 1 Capecitabine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × HER2 Positive Breast Cancer × pertuzumab × Clear all

NCT01904903 2022-05-10

SAFE-HEaRt

Medstar Health Research Institute

Phase 2 Completed

31 enrolled 12 charts

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡